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Summary.-ICRF 159 and Triton WR 1339 have been examined for their ability
to suppress subcutaneous growth and pulmonary metastases from a transplanted
rat epithelioma. Neither compound influenced subcutaneous tumour development
or reduced the propensity to metastasize when administered in regimens reported
to suppress pulmonary, lymph node or intracerebral metastases in other experi-
mental systems.
A NUAIBER of chemotherapeutic agents
have recently been investigated for their
selective inhibition of metastases from
experimental animal ttimours (reviewe(d
by Garattini and Franchi, 1973). The
objective of the present investigation
was to assess the anti-metastatic effect
of two compounds, ICRF 159 and Triton
WR 1339, on the development of pul-
monary metastases from a syngeneically
transplanted rat epithelioma. Both of
these compounds have been reported as
having potential anti-metastatic effects
in other animals studies, although they
are thought to have widely differenit
modes of action.
ICRF 159 [(±)-l,2-bis(3-5-dioxopiper-
azin-1-yl)propane] has been reported to
inhibit selectively the development of
pulmonary metastases from subcutaneous
or intramuscular grafts of the Lewis lung
carcinoma in C57BI mice (Salsbury,
Buirrage and Hellmann, 1970; Hellman
and Burrage, 1969; Franchi and Garattini,
1.973). Althouigh a powerful anti-mitotic
(Sandberg and Goldin, 1971), the com-
pound dloes not inhibit growth of primary
implants of Lewis lung carcinoma at
doses effective in inihibiting pulmonary
metastases. In ICRF 159 treated mice,
however, changes occur in the (leveloping
primary tiumour implaniit, with imiorplhto-
logical and ftunctional niormalization of
vasculature (Salsbury et al., 1970; Le
Serve and Hellmann, 1972). The pre-
sence in ICRF 159 treated animals of a
well formed vasculature between tumour
cells and blood has been interpreted as
the main factor in preventing haemato-
genous tumour spread (Salsbury et al.,
1970; Hellmann et al., 1973). The clinical
application of ICRF 159 to the treatment
of acute leukaemia and lymphosarcoma
has been described (Hellmann et al.,
1969), although the beneficial effects
reported in these cases were interpreted
as due to the drug's anti-mitotic action.
Triton WR 1339 (polyoxyethylene
ether of formaldehyde polymers of acetyl-
phenol) a non-ionic surfactant, has been
reported to modify metastasis in a number
of experimental systenms, with no in-
fluence on the growth of initial tumour
implants. Thus, WR 1339 treatment
suppresses the formation of pulmonary
metastases from intramuscuilar grafts of
the Lewis lung carcinoma (Franchi et
al., 1971; Franchi and Garattini, 1971,
1973), lymph node metastases from intra-
tibial transplants of Ehrlich carcinoma
(Rosso et al., 1969; Franchi et al., 1971)
and pulmonary nietastasis ofintracerebral
implants of sarcoma 180 or Ehrlich
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1969; Franchi et al., 1971). Enhancement
of metastases has, however, been reported
with other animal tumours treated with
Triton WR 1339. With a transplanted
metastasizing lymphoma in hamsters,
Triton WR 1339 treatment reduced the
growth of initial tumour inocula but
increased the propensity to metastasize,
particularly to the liver (Carter, Birbeck
and Stock, 1971; Cotmore and Carter,
1973). In addition, the compouild in-
creases the formation of metastases from
intracaecal implantations of tumours in
the mouse (Franchi and Garattini, 1973).
The biological effects of Triton WR
1339 are complex, involving enhancement
of the reticuloendothelial system, with
activation ofmacrophage lysosomes (Fran-
chi and Garattini, 1973; Franchi et al.,
1971). Its anti-metastatic effects are
thought to be due to binding to tumour
cell surfaces, altering their movement
and potential for attachment, and thus
facilitating host recognition and destruc-
tion of cells liberated from the initial
tumour mass (Francbi et al., 1971;
Franchi and Garattini, 1973; Morasca,
1973). The compound does not influence
the growth of tumour cells already
lodged in other organs (Franchi et al.,
1971).
In the present studies, the ability
of these two compounds to influence
the development of spontaneous pul-
monary metastases from a subcutaneously
transplanted rat epithelioma has been
investigated. This tumour is currently
being used to explore immunotherapeutic
techniques for the control of metastases
(Baldwin and Pimm, 1973), and the
results of the present studies are com-
pared and contrasted with those achieved
by immunotherapy.
MATERIALS AND METHODS
Epitheliomia Spl. Epithelioma SpI arose
spontaneously in a female rat in the inbred
Wistar strain of the department, and was
maintained by subcutaneous transplantation
in syngeIneic female rats. In the present
a
studies, the tumour was in its 32-36th
transplant generation. This tumour regu-
larly produces pulmonary metastases from
subcutaneous grafts (Baldwin, 1966; Baldwin
and Pimm, 1973).
ICRF 159.-ICRF 159 was supplied by
Dr K. Hellmann, Imperial Cancer Research
Fund, London. The compound was suspend-
ed in sterile 0-50o (w/v) carboxymethyl-
cellulose in 0-15 mol/l saline (CMC-saline)
to a concentration of 6-12 mg/ml.
Triton WR 1339.-Triton WR 1339 was
supplied by Professor S. Garattini, Mario
Negri Institute forPharmacological Research,
Milan, Italy. The material was dissolved
in water at 100 mg/ml and sterilized by
filtration through a 0-22 ,m Millipore
filter.
Methods of treatment.-Subcutaneous
growths of epithelioma Spl were produced
by trocar implantation of fragments of
tumour tissue into adult female rats (111-
150 g body weight). Treatment with ICRF
159 was effected by repeated intraperitoneal
injections of the compound in CMC-saline
suspension at 30 mg/kg body weight. Con-
trol rats received injections of CMC-saline
alone. Triton WR 1339 was also administer-
ed by repeated intraperitoneal injection, at
500-1250 mg/kg body weight. In some
experiments, subcutaneously developing tu-
mour grafts were removed surgically when
they reached approximately 1 cm mean
diameter.
Assessment of tumour growth and meta-
stasis.-Subcutaneously developing tumours
were measured with calipers twice weekly
and average diameters calculated from
measurements in 2 planes. Pulmonary meta-
stases were demonstrated by perfusion of
lungs with diluted India ink, followed by
fixation in Fekete's solution (Wexler, 1966).
The numbers of macroscopically visible
lung surface nodules were counted. When
the number of nodules was greater than
200 the result was scored as 200+. Each
experiment was terminated whenthe majority
of animals exhibited respiratory distress,
due to pulmonary metastases, or when
subcutaneous tumours had reached 3-4 cm
diameter.
RESULTS
ICRF 159
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TABLE I.-Influence of ICRF 159 on Subcutaneous Growth and Pulmonary
Metastasis of Rat Epithelioma SpI
ICRF 159
treatment*
Expt (dayst)
1 0, 1,2,3,4,5,6
2 0, 1,2,3,4,6,7,
8, 9, 10, 12, 14
3 0, 1,2,3,4
4§ 3, 4, 5, 6, 7, 8, 10
Experiment
terminated
(day)
16
16
21
21
23
23
20
20
Mean tumour
diameter (cm)
±s.e.
3-2±0 7
3-8 0- 7
3- 6±0-5
4-1±0 7
3 0±0 5
3 3±0 5
No. of
rats with
pulmonary
metastases
5/5
5/5
5/5
5/5
5/5
4/5
4/4
4/5
* 30 mg/kg body weight intraperitoneally.
t With respect to tumour implantation.
t From Wilcoxon rank test.
§ In this experiment subcutaneous tumours were excised
159 treatment on the development of metastases
pulmonary metastases in rats with sub- cantly dif
cutaneous grafts of epithelioma Sp1. numbers ir
In the first experiment, rats received 7 monary tu
daily intraperitoneal injections of ICRF only 4/5 ra
159 in CMC-saline (30 mg/kg body weight), In the
starting on the day of tumour implanta- veloping t
tion, and control rats received injections control rat
of CMC-saline alone. The treatment had the end of
no influence on the growth of subcu- ment. In
taneous tumours, so that when the had develo
experiment was terminated after 16 days 79 nodules;
both treated and control animals had ment was
large subcutaneous growths (mean dia- animals als
meters 3-2 cm and 3-8 cm respectively). pulmonary
In addition, analysis of the numbers of
pulmonary metastases showed that both Triton WE
control and treated rats all had over 200
metastatic pulmonary nodules. The resi
In a second test, animals were treated ment on ti
with 12 injections of ICRF 159 during metastases
the first 14 days after tumour implanta- shown in T
tion, and by 21 days, when the experi- In the fi
ment was terminated, tumour sizes were grafts rece
comparable in treated and control rats. WR 1339
All control animals, and 4/5 ICRF 159 during the
treated rats, developed in excess of 200 tumour dev
pulmonary metastases and the remaining erted no:
treated rat also had multiple macro- subcutaneol
scopically visible tumour deposits in the and control
lung (70 nodules). of pulmona
In a further test, ICRF 159 treated the experi
rats developed only 3-67 pulmonary 22 days.
Pulmonary
metastases
No./lung
5 x 200+
5 x 200+
70, 4x200+
5 x 200+
3, 3, 7, 23, 67
0, 15, 49, 53, 200+
4, 42, 47, 87
0, 2, 11, 23, 79
Pt
0-20
0O10
11 days after implantation.
but these were not signifi-
ferent (P 0.20) from the
n control animals where pul-
mour deposits were found in
ts (15-200 nodules).
final test, subcutaneously de-
fumours in both treated and
ts were removed surgically at
the period of ICRF 159 treat-
this case, 4/5 control rats
ped pulmonary metastases (2-
by Day 20 when the experi-
terminated. All (4/4) treated
so had metastases, with 4-87
tumour deposits (P _ 0.10).
1339
tults of Triton WR 1339 treat-
he development of pulmonary
from epithelioma Sp1 are
able II.
irst test, rats with Spl tumour
ived 15 injections of Triton
(500 mg/kg body weight)
first 20 days of subcutaneous
zelopment. The treatment ex-
influence on the growth of
us grafts and both treated
I rats had comparable numbers
try metastases (P= 0.7) when
iment was terminated after
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TABLE II.-Influence of Triton WR 1339 on Subcutaneous Growth and Pulmonary
Metastasis of Rat Epithelioma Spl
AMg/kg
body
Expt wrt
1 500
Tritoii WR 1339
treatment
Day*
3, 4, 5, 6, 7, 8, 10, 11,
12, 13, 14, 17, 18,19,
20
2 500 0, 1, 2, 3, 4, 7, 8, 9, 10,
]1
1250 0, 4, 8, 11
31 500 3, 4, 5, 6, 7, 8, 10, 11,
12, 13, 14, 17, 18 ,19,
20
Experinent
terminiate(l
(day)
22
AMean tumour
diameter (cm)
±s.e.
2-8-0-2
22 2-6±0-2
24 3 4±0 5
24
24
20
20
3 3±0 5
3 3±0 5
-No. of
rats with
pulmonary
metastases
5/5
Pulmonary
metastases
No./lung
13, 32, 40, 57, 200
5/5 4, 4, 12, 25, 165
4/5 0, 30, 50, 59, 68
4/4
4/5
5/5
3, 88, 200+, 200+
0, 15, 49, 53, 200+
73, 134, 147, 200+,
200+
4/5 0, 2, 11, 23, 79
Pt
0 7
0-6
0-2
0*01
* With respect to ttumour implantation.
t From Wilcoxon rank test.
+ In this experiIneInt subctutaineous tuinoturs were excise(l 11 (lays after implantation.
In the second test, rats were treated
with a total of 5000 mg/kg body weight
of Triton WR 1339, either as 10 inject-
ions of 500 mg/kg or 4 injections of
1250 mg/kg. Again, however, neither
treatment influenced the growth of
subcutaneous tumours or significantly
altered the numbers of pulmonary meta-
stases.
In a final test, in addition to repeated
administration of Triton WR 1339
throughout the entire course of the
experiment, rats were treated by surgical
removal of subcutaneously growing tu-
mour grafts 11 days after their implanta-
tion. In this case there was statistically
significant enhancement of pulmonary
metastases. Thus, 5/5 treated rats de-
veloped 73-200 metastatic nodules while
the 4/5 control rats which developed
metastases had only 2-79 pulmonary
tumouLr nodules (P 0 01).
DISCUSSION
These studies demonstrate that neither
ICRF 159 or Triton WR 1339 significantly
influences the subcutaneous development
of epithelioma Spl, nor do they restrict
pulmonary metastases, even in rats from
which tumour growths have been removed
surgically.
The dosage (30 mgfkg) and time of
administration of ICRF 159 were com-
parable with those reported by Hellmann
and Burrage (1969) to suppress the
development of pulmonary metastases
from subcutaneous grafts of the Lewis
lung carcinoma, where injection of the
compound during the first or second
7 days after tumour implantation elimin-
aged metastases almost completely. In
addition, treatment of mice with 9 doses
of only 7 5 mg/kg were reported to
partially restrict metastases from the
Lewis lung carcinoma (Franchi and Garat-
tini, 1973).
In the present studies, prolonged
administration of the drug (12 x 30
mg/kg) to rats with epithelioma Sp1
grafts did not influence the eventual
metastases in these animals. With the
Lewis lung carcinoma, the suppression
of metastases by ICRF 159 is caused by
failure of tumour cells to enter the blood
from the initial tumour graft, since no
circulating malignant cells are found in
drug treated mice, in comparison with
untreated animals (Salsbury et al., 1970).
In the present studies, however, chemo-
therapy with ICRF 159 in conjunction66 M. V. PIMM AND R. W. BALDWIN
with surgical excision of epithelioma Sp1
grafts failed to restrict the development
of pulmonary metastases. In this case
tumour grafts were excised one day after
the administration of ICRF 159 had
ended. Thus, metastases ultimately
found in these rats could not have been
formed by tumour cells allowed to enter
the blood after the drug had been with-
drawn and therefore must have been
produced from tumour cells disseminated
during ICRF 159 administration.
With Triton WR 1339, repeated ad-
ministration of the compound at 500
mg/kg body weight, or every 4 days at
1250 mg/kg, failed to influence the
subcutaneous growth or pulmonary meta-
stases of Sp1. In contrast, metastases
from tumours implanted intratibially,
intracerebrally or intramuscularly in the
mouse were restricted by similar regimens
of chemotherapy (Franchi et al., 1971)
and daily injections of only 50 mg/kg
inhibited the formation of pulmonary
metastases from the Lewis lung carcinoma
(Franchi and Garattini, 1971).
In the one present experiment where
Triton was given repeatedly both during
subcutaneous growth of epithelioma Spl
and after surgical removal of tumour
grafts, treatment again failed to suppress
metastases and the indication is that
pulmonary metastasis was enhanced by
the procedure. With a metastasizing
hamster lymphoma Cotmore and Carter
(1973) found that hepatic metastases
were increased by Triton treatment. They
interpreted this as due to Triton induced
damage of hepatic sinusoidal and Kupffer
cells, encouraging trapping or growth of
malignant cells in the liver.
In contrast to the present findings,
pulmonary metastasis from epithelioma
Spl can be restricted by immunothera-
peutic methods involving contact of
tumour cells with bacillus Calmette-
Guerin (B.C.G.) organisms (Baldwin and
Pimm, 1973). Thus, subcutaneous injec-
tion of tumour cells in admixture with
B.C.G. both retarded local tumour de-
velopment and reduced the propensity
to metastasize. Furthermore, pulmonary
metastases appearing after surgical re-
moval of tumour grafts were restricted,
and in a proportion of animals completely
abolished, by intravenous injection of
B.C.G. organisms.
In conclusion, these studies indicate
that chemotherapeutic agents having anti-
metastatic effects in some experimental
circumstances may not be generally
effective, and may even encourage meta-
stases, although the mechanisms of both
suppression and enhancement are complex.
Immunotherapeutic methods may be a
feasible alternative to chemotherapy for
the control of metastases, at least in
the lung.
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